News

The idiopathic pulmonary fibrosis (IPF) treatment candidate BBT-877 eased lung fibrosis (scarring) in a mouse model, according to South Korea-based Bridge Biotherapeutics. The company believes that BBT-877 may become the “best-in-class” medication for IPF. Data from a preclinical study on BBT-877 was presented at the 2nd Annual IPF…

A gene therapy designed to fight pulmonary fibrosis (PF) by extending the lifespan of lung cells has been found safe and does not cause or increase the risk of cancer in the lungs, despite some concerns to the contrary, a mouse study shows. Earlier this year, a research team at…

The European IPF registry offers important insights into the characteristics, care management, and outcomes of idiopathic pulmonary fibrosis (IPF) patients in Europe, a study reports. Data from the registry showed that the most common symptoms reported by IPF patients are breathing difficulties, fatigue, and a dry cough, according to the…

A plant-based medicine called quercetin reversed pulmonary fibrosis in a mouse model likely by reducing the burden of growth-arrested and fibrosis-promoting cells, called senescent cells, in the animals’ lungs, researchers report. Findings were published in the study, “Quercetin enhances ligand-induced apoptosis in senescent IPF fibroblasts and reduces lung…

Laparoscopic surgery in idiopathic pulmonary fibrosis (IPF) patients with acid reflux is safe and well-tolerated, but does not appear to significantly ease the decline in respiratory function that’s thought to be aggravated by reflux, according to a Phase 2 study. The research, “Laparoscopic anti-reflux surgery for…

Surgery for lung cancer should be carefully considered in patients who also have idiopathic pulmonary fibrosis (IPF), because it is associated with poor outcomes, a study shows. The study, “Survival after repeated surgery for lung cancer with idiopathic pulmonary fibrosis: a retrospective study,” was published in the journal…

Tiny extracellular vesicles that carry information from one cell to another may contribute to the development of idiopathic pulmonary fibrosis (IPF) by carrying molecules involved in the disease, a study has found. The study, “Increased Extracellular Vesicles Mediate WNT-5A Signaling in Idiopathic Pulmonary Fibrosis,” was published in the…

Lung cancer and acute exacerbations are significant predictors of mortality in patients with combined pulmonary fibrosis and emphysema, according to researchers. Their study, “Presence of lung cancer and high gender, age, and physiology score as predictors of acute exacerbation in combined pulmonary fibrosis and emphysema: A…

A recent study has provided more insight into the molecular processes that might be involved in the pathological changes that take place in the lungs of patients with idiopathic pulmonary fibrosis (IPF). In the study, “A role for telomere length and chromosomal damage in idiopathic pulmonary fibrosis,”…

Pliant Therapeutics announced that its lead therapy candidate PLN-74809 was designated an orphan drug by the U.S. Food and Drug Administration (FDA), an act that helps to advance its development as a possible treatment of…